Using Nanotechnology Structured Water to Control Blood Glucose in Type 2 Diabetic Patients.

ALI KAMAL M. SAMI

Status: Completed

Conditions: Type2 Diabetes

Treatments: Dietary Supplement: Nanotechnology structured water ( Magnalife); Dietary Supplement: ordinary water

Study type: Interventional

Funder types: Other

Identifiers

NCT04082351

USulaimani

Details and patient eligibility

About

Type 2 DM is due to insulin resistance or low insulin secretion or sometimes a combination of both. Nanotechnology structured water is a type of water that is produced using energy field modulators to change the biological, chemical, and physical properties of water molecules and improve the bioavailability of this nano-water. Objective: To find out the effect of drinking nanotechnology structured water (Magnalife®) on the blood glucose levels in patients with type 2 diabetes mellitus.

Full description

This is a blind randomized control trial, according to CONSORT guidelines for randomization, "Participants were randomly assigned following simple randomization procedures (computerized random numbers) to 1 of 2 treatment groups.", that included 387 patients with Type 2 diabetes mellitus in Diabetes Care Center, Sulaymaniyah, Kurdistan region from July 2016 till February 2018. A total of 387 patients with type 2 diabetes who were patients in this center and agreed to participate in this clinical trial were included in this study.

In group A, patients were given nanotechnology structured water Magnalife® and in group B they were given ordinary bottled drinking water as a control . The bottles were unlabeled so that the patients did not know which water they were drinking. Then they were asked to eat their usual food and to drink their usual drinks, also they could drink water ad libitum after drinking the daily doses, and to have the same physical activities that they used to do in their usual daily life. They were instructed to take their medications as usual, and were told to come to test their blood sugar level at the end of the third month to get the HbA1c tested at the end of the three months of drinking the water.

Enrollment: 387 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Type 2 diabetic patients

Exclusion criteria

• Malignancy
• Steroids
• Immunotherapy
• Chemotherapy
• Radiotherapy
• Chronic infections
• Drugs that antagonize or synergies insulin effects

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

387 participants in 2 patient groups, including a placebo group

Magnalife

Active Comparator group

Description:

the group of patients receiving the nanotechnology structured water

Treatment:

Dietary Supplement: Nanotechnology structured water ( Magnalife)

Ordinary water

Placebo Comparator group

Description:

the group of patients receiving ordinary water

Treatment:

Dietary Supplement: ordinary water